Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

Signaling Pathways in Disease

Signaling Pathways in Disease is a research topic within Molecular Biology. Science Explorer counts 24k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the role of Calcineurin-NFAT signaling in transcriptional regulation, with a particular emphasis on its involvement in cancer progression, cardiac hypertrophy, and inflammatory responses. The cluster also explores the impact of Prolyl Isomerase Pin1, EMMPRIN/CD147, and immunophilins in modulating this signaling pathway.

  • Calcineurin
  • NFAT
  • Transcriptional Regulation
  • Prolyl Isomerase Pin1
  • Cancer Progression
  • Cardiac Hypertrophy
  • Immunophilins
  • EMMPRIN/CD147
  • Peptidyl-Prolyl Isomerases
  • Inflammatory Responses
Research works
24k
fractional, since 1950
In the world top 10%
2.3k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-3%
the tick is no change
Largest producer
China
46% of the 10 largest, 2022-now
Signaling Pathways in Disease

Which countries lead Signaling Pathways in Disease research?

By volume, China and the United States publish the most (1.1k and 587 works in 2022-now).

By volume, 2022-now

  1. 1 China 1.1k works
  2. 2 United States 587 works
  3. 3 Germany 137 works
  4. 4 Japan 108 works
  5. 5 India 104 works
  6. 6 United Kingdom 82 works
  7. 7 South Korea 73 works
  8. 8 Italy 68 works
  9. 9 France 58 works
  10. 10 Canada 55 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 45.5%United States: 25.2%Germany: 5.9%Japan: 4.6%6 others listed: 18.8%46%largest
China1,062 · 45.5%United States587 · 25.2%Germany137 · 5.9%Japan108 · 4.6%6 others listed439 · 18.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Signaling Pathways in Disease research?

By volume in 2022-now, Sun Yat-sen University publishes the most Signaling Pathways in Disease research, followed by Shanghai Jiao Tong University and Nanjing Medical University.

By volume, 2022-now

  1. 1 Sun Yat-sen UniversityChina 28 works
  2. 2 Shanghai Jiao Tong UniversityChina 27 works
  3. 3 Nanjing Medical UniversityChina 22 works
  4. 4 Zhejiang UniversityChina 22 works
  5. 5 Chinese Academy of SciencesChina 21 works
  6. 6 Harvard UniversityUnited States 21 works
  7. 7 Huazhong University of Science and TechnologyChina 20 works
  8. 8 Sichuan UniversityChina 18 works
  9. 9 Fudan UniversityChina 18 works
  10. 10 National Institutes of HealthUnited States 18 works

Who are the leading researchers in Signaling Pathways in Disease?

The most-cited researchers publishing on Signaling Pathways in Disease include Peer Bork, Guido Kroemer and John J.V. McMurray.

  1. 1 Peer Bork Germany 396k citations
  2. 2 Guido Kroemer France 386k citations
  3. 3 John J.V. McMurray United Kingdom 349k citations
  4. 4 Jun Wang China 340k citations
  5. 5 Giuseppe Remuzzi Italy 328k citations
  6. 6 Gregory Y.H. Lip United Kingdom 311k citations
  7. 7 Matthias Mann Germany 308k citations
  8. 8 Róbert Langer United States 303k citations
  9. 9 John Q. Trojanowski United States 286k citations
  10. 10 Todd R. Golub United States 283k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Signaling Pathways in Disease?

The most cited paper in Signaling Pathways in Disease is "Calcium's Role in Mechanotransduction during Muscle Development" (Tatiana Benavides Damm, Marcel Egli, 2014), with 14,545 citations. Next come "Integrins" (8,635) and "Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor" (6,632).

Most cited papers
#PaperReleasedCitations
1 Calcium's Role in Mechanotransduction during Muscle Development Tatiana Benavides Damm, Marcel Egli · Cellular Physiology and Biochemistry Open access 2014 14,545
2 Integrins Richard O. Hynes · Cell Open access Sep 2002 8,635
3 Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor Anne Sophie Brunet, Azad Bonni, Michael J. Zigmond et al. · Cell Open access Mar 1999 6,632
4 Inositol trisphosphate and calcium signalling Michael John Berridge · Nature 1993 6,606
5 New functions for the matrix metalloproteinases in cancer progression Mikala Egeblad, Zena Werb · Nature reviews. Cancer Review Mar 2002 6,127
All 100 most cited papers, with filters and sorting

Where is Signaling Pathways in Disease research done?

The largest centres of Signaling Pathways in Disease research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Guangzhou.

Largest cities, 2022-now

  1. 1 BeijingChina 109 works
  2. 2 ShanghaiChina 95 works
  3. 3 GuangzhouChina 80 works
  4. 4 NanjingChina 51 works
  5. 5 WuhanChina 50 works
  6. 6 HangzhouChina 40 works
  7. 7 ParisFrance 29 works
  8. 8 ChengduChina 29 works
  9. 9 SeoulSouth Korea 29 works
  10. 10 ChangshaChina 28 works

Where it is the local speciality

  1. GuangzhouCN · 79.6 works3.3×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Signaling Pathways in Disease than the world average.

See Signaling Pathways in Disease on the map

Where is the best place to study Signaling Pathways in Disease?

Among universities, judged by research, Harvard University, Huazhong University of Science and Technology and Zhejiang University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 17.35%fractional works in this field (log) →share of work in the world top 10% →Huazhong University …Zhejiang UniversityHarvard UniversityShanghai Jiao Tong U…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 69.415.3%2.7×21 -21.6%
2Huazhong University of Science and TechnologyChina 66.721.7%4.5×20 +8.0%
3Zhejiang UniversityChina 64.117.5%3.3×22 +30.9%
4Shanghai Jiao Tong UniversityChina 62.614.1%3.8×27 +4.5%
5Wuhan UniversityChina 59.719.9%5.0×18 -3.0%
6Fudan UniversityChina 58.317.2%4.6×18 +41.1%
7Stanford UniversityUnited States 57.316.8%2.6×10 +8.0%
8Southern Medical UniversityChina 56.113.5%10.2×16 +120.0%
9Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 55.912.8%6.8×18 +31.4%
10Tongji UniversityChina 55.524.7%2.4×9 +41.1%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Signaling Pathways in Disease, country by country

Is Signaling Pathways in Disease research growing?

Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2014.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Signaling Pathways in Disease as a percentage of every work published that year, 0.012% in 2024.

still counting0.020%0.040%0.060%Signaling Pathways in Disease0.012% in 202519801990200020102020

Fractional works of Signaling Pathways in Disease over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Signaling Pathways in Disease10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Signaling Pathways in Disease. Posts are plain text and can be reported.